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Abstract
Background: At present, inconsistent association between single nucleotide polymorphism (SNP) in pre-miRNAs
(hsa-mir-196a2 rs11614913 C/T, hsa-mir-499 rs3746444 A/G, and hsa-mir-146a rs2910164 C/G) and bladder cancer
were obtained in limited studies. We performed a case–control study to test whether these three common
polymorphisms are associated with bladder cancer. One hundred fifty-nine patients affected by bladder cancer
and 298 unrelated healthy subjects were enrolled in the study.
Methods: Using polymerase chain reaction–restriction fragment length polymorphism assay (PCR–RFLP), genotypes
of these three SNPs were determined, and their associations with bladder cancer, as well as with clinic pathological
factors, and tumor progression were analyzed.
Results: No association between bladder cancer risk and variant allele of hsa-mir-196a2 rs11614913 C/T, hsa-mir-499
rs3746444 A/G, or hsa-mir-146a rs2910164 C/G was observed. Heterozygous genotype (CT genotype) of rs11614913
was associated with a significantly decreased bladder cancer risk (P = 0.004, OR = 0.56, 95 % CI = 0.38–0.83). Further
stratified analyses showed that rs2910164 is associated with the tumor stage in a recessive model and with
metastasis in a dominant model (P = 0.012, OR = 0.20, 95 % CI = 0.05–0.72 and P = 0.04, OR = 2.63, 95 % CI = 1.03–6.67,
respectively). No association between hsa-mir-499 rs3746444 A/G and bladder cancer was observed.
Conclusions: Our results suggested hsa-mir-196a2 rs11614913 C/T is associated with a significantly decreased risk
of bladder cancer and hsa-mir-146a rs2910164 GG genotype is associated with clinical stage and metastasis in
bladder cancer.
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Background
As the most common malignant tumor of the urinary
tract, it is estimated that there were 74,690 new cases
and 56,390 patients died from bladder cancer in United
States in 2014 [1]. Tobacco smoking and chemical carcin-
ogens are the two well-established external environmental
factors of bladder cancer [2]. Besides, accumulating evi-
dence indicates that inappropriate diet and lifestyle
may have a relationship with bladder cancer [3]. These
factors could be an explanation for the rising morbidity
of bladder cancer all over the world. It is worth noting
that the majority of exposed individuals do not suffer
from bladder cancer in their lifetime. This phenomenon
suggested that other causes, such as the genetic factor
may also play a role in bladder carcinogenesis.
MicroRNAs (miRNAs) are a class of ancient, non-
coding, and single-stranded molecules that participate in
transcriptional and translational regulation by pairing
with target mRNAs [4]. Although represents only 1–4 %
in the human genome, a single miRNA can regulate ap-
proximately 200 target mRNAs [5]. This means that
miRNAs may play critical roles in a diverse range of bio-
logical processes, such as cell proliferation, tissue differ-
entiation, embryonic development, and apoptosis [5, 6].
Mutation of miRNAs and dysregulation of miRNAs and
their targets genes have been observed in various diseases
and several reports have demonstrated that miRNA plays
an important role during carcinogenesis [7, 8].
Single nucleotide polymorphism (SNP) is the most
common type of genetic variation that usually appears in
miRNA coding genes, miRNA biogenesis genes, or in
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the miRNA-binding sites of mRNAs. The variations may
alter the expression and function of miRNA, which may
relate to the tumorigenesis [9]. Recently, two studies
analyzed the relationship between common SNPs in
pre-miRNAs and urinary bladder cancer [10]. While
one obtained the negative results, the other indicates
that miR-146a rs2910164 plays an important role in
bladder cancer. In addition, they have associated the C
allele with a significantly decreased risk and recurrence
of bladder cancer [11]. To clarify the inconclusive re-
sults of previous studies, we explored the association
between these three SNPs (rs2910164, rs11614913, and
rs3746444) in pre-miRNAs (hsa-mir-146a, hsa-mir-196a2,
and hsa-mir-499, respectively) and the risk of bladder
cancer in a population of southwest China.
Methods
Patients and controls
All participants were form the Han population living
in Sichuan Province of China and examined at the De-
partment of urology, West China Hospital of Sichuan
University. This study was approved by the Investigation
and Ethics Committee of the West China Hospital of
Sichuan University. Details were told to all participants
and written informed consent was signed after the inter-
view. The present study enrolled 159 unrelated patients
with bladder cancer (124 men and 35 women, mean age:
64.09 ± 12.31) from the West China Hospital of Sichuan
University between 2009 and 2012. The clinical diagnosis
of bladder cancer was based on histopathologically con-
firmed specimens. Two hundred ninety-eight unrelated
healthy individuals (140 men and 158 women, mean age:
60.21 ± 11.32) from a routine health survey were enrolled
as controls. Patients who previously had cancer, radiother-
apy and chemotherapy, or metastasized cancer from other
or unknown origins were excluded. Control subjects were
genetically unrelated individuals, and those with history of
bladder cancer or other type of illness were excluded in
this study.
Genotyping
Three SNPs, including hsa-mir-196a2 rs11614913 C/T,
hsa-mir-499 rs3746444 A/G, and hsa-mir-146a rs2910164
C/G were genotyped by the PCR–RFLP method. The
instruction manual details that 300 μl of EDTA-
anticoagulated peripheral blood samples should be
collected from the patients and that their genomic
DNA be isolated by a DNA isolation kit from Bioteke
(Peking, China).
PIRA PCR designer (http://primer1.soton.ac.uk/primer2.
html) was used to establish primers. The primers are used
for amplification of these three SNPs and their specific re-
striction enzyme was shown in Table 1. The PCR reactions
mixture was consisted of 2.0 μl 10× PCR buffer, 1.5 mmol/
L MgCl2, 0.2 mmol/L dNTPs, 0.4 μmol/L each primer,
100 ng of genomic DNA and 1 U of Taq DNA polymerase.
Briefly, cycling parameters were summarized as follows:
94 °C for 2 min; 30 cycles at 94 °C for 30 s; 30 s with differ-
ent temperature parameters: 62 °C for rs11614913, 66 °C
for rs3746444 and 58 °C for rs2910164; 45 s at 72 °C and
the last extension procedure at 72 °C for 7 min. PCR–RFLP
assay was used to obtained the genotypes of the three SNPs:
rs11614913 C/T, rs3746444 A/G, rs2910164 C/G [12].
Two researchers, who were irrelevant for this study,
viewed the results independently. If there is no consen-
sus, repeated assays would be required. Besides, 10 %
duplicated samples were randomly selected to perform
for the three SNPs, with a concordance rate of 100 %.
Statistical analysis
Genotypic frequencies of the observed SNPs were avail-
able by directly counting and the χ2 test was used to
evaluate the Hardy-Weinberg equilibrium. Data were
carried out by using computer software SPSS (SPSS Inc.,
Chicago, IL, USA) and odds ratio (OR) and respective
95 % confidence intervals (95 % CI) were reported to
compare the differences between the two groups. Geno-
typic association tests were conducted by using SNPstats,
including codominant, dominant, recessive, overdominant,
and log-additive genetic models [13].
Results and discussion
Genotyping for all the three SNPs were performed in
159 bladder cancer patients and 298 control subjects.
As expected, the results showed genotype frequencies
for these three SNPs in control subjects were consistent
with those from the Hardy-Weinberg equilibrium. Allele
frequencies of rs11614913 C/T, rs3746444 A/G, and
rs2910164 C/G in bladder cancer patients and controls
are summarized in Table 2. As shown in Table 2, no sig-
nificant difference for the allele frequencies of these three
SNPs was observed between bladder cancer patients and
control subjects (P = 0.976 for rs11614913, P = 0.348 for
rs3746444, and P = 0.417 for rs2910164). Results of geno-
typic association tests performed by SNPstats are shown
in Table 3. As shown in Table 3, significant association
was identified for rs11614913 in an overdominant model.
Compared with the combined homozygous genotypes
(TT/CC genotypes), a significant decrease in bladder can-
cer risk was associated with the heterozygous genotype
(CT genotype) of rs11614913 (P = 0.004, OR = 0.56, 95 %
CI = 0.38–0.83). No association between the rs3746444
and rs2910164 genotypes and bladder cancer risk was ob-
served in codominant, dominant, recessive, overdominant,
or log-additive genetic model. These results suggest that
the mir-196a2 rs11614913 C/T, but not the mir-499
rs3746444 A/G or the mir146a2 rs2910164 C/G, was asso-
ciated with bladder cancer in the Chinese population
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studied. This indicates that polymorphisms in pre-
microRNAs may play a role in the pathogenesis of
bladder cancer.
Further analysis stratified bladder cancer patients’
characteristics including age, gender, smoking status,
tumor stage, tumor grade, recurrence, and metastasis.
As shown in Table 4, rs2910164 was found to be associ-
ated with the tumor stage in a recessive model (P = 0.012,
OR = 0.20, 95 % CI = 0.05–0.72). Table 5 shows that
rs2910164 is associated with metastasis in a dominant
model (P = 0.04, OR = 2.63, 95 % CI = 1.03–6.67). No
association was observed between these three SNPs and
bladder cancer patients’ age, gender, smoking status,
tumor grade, or recurrence (data not shown).
In the present study, the association between SNPs in
pre-miRNAs and bladder cancer, as well as with patients’
characteristics, such as age, gender, tumor grade, tumor
stage, smoking status, recurrence, and metastasis were
analyzed. Our results revealed that hsa-mir-196a2
rs11614913 C/T is associated with bladder cancer in
an overdominant model. Similarly, the hsa-mir-146a
rs2910164 is associated with the tumor stage in recessive
model and with metastasis in dominant model, respect-
ively. Hsa-mir-499 rs3746444, however, is not associated
with bladder cancer or any of the patients’ characteristics.
The miRNAs were composed of 21 to 24 nucleotides
which can provide sequence specificity to RNA silencing
pathway by pairing with target mRNAs [14]. Myriad evi-
dence has indicated that miRNA is involved in diversity
of biological process and many human genes are under its
regulation, as well as some well-known tumor suppressor
genes [5, 15]. Nowadays, the roles of altered miRNA
expression in various diseases have been well established,
including malignant cancer [7]. Gottardo and his colleagues
analyzed the expression profile of miRNAs in bladder
cancer and found that some miRNAs are significantly
deregulated in bladder cancer compared with normal
bladder mucosa, suggesting the involvement of these
genes in the development and progression of bladder
cancer [16]. Additionally, several additional miRNA-related
SNPs have been demonstrated to be associated with
bladder cancer risk, this means that miRNA-related
SNPs are involved in mechanism of bladder carcino-
genesis [17].
Emerging studies have reported the association be-
tween the hsa-miR-196a2 rs11614913 polymorphism
and susceptibility to several types of cancers, including
hepatocellular carcinoma, gastric cancer, and breast
cancer [18–20]. MiR-196a is one of the mature products
encoded by miR196a2 gene, and miR-196a* which con-
tains the SNP rs11614913 is the other mature product
[20]. Hoffman et al. showed relative to empty vector
control, the expression of mature miR-196a is increased
in breast cancer cells both transfected with pre-miR-
196a-C or miR-196a-T. Moreover, levels of the mature
miR-196a were more than double in cells transfected
with pre-miR-196a-C than those with miR-196a-T [20].
This finding suggested that SNP rs11614913 can affect
the processing of the pre-miRNA into its mature, func-
tional form, and this polymorphism might be a risk fac-
tor of tumorigenesis. This present study’s findings
reveal that rs11614913 is associated with bladder cancer in
Table 1 Primers and restriction enzyme used for analysis of these three SNPS
SNPs Primers (5′–3′) Products (bp) Restriction enzyme
hsa-mir-196a2 rs11614913 C/T F: CCCCTTCCCTTCTCCTCCAGATA 149 MspI
R: CGAAAACCGACTGATGTAACTCCG
hsa-mir-499 rs3746444 A/G F: CAAAGTCTTCACTTCCCTGCCA 146 BclI
R: GATGTTTAACTCCTCTCCACGTGATC
hsa-mir-146a rs2910164 C/G F: CATGGGTTGTGTCAGTGTCAGAGCT 147 SacI
R: TGCCTTCTGTCTCCAGTCTTCCAA
Table 2 Allele frequencies of selected SNPs in pre-microRNAs among bladder cancer patients and controls
SNP Allele Patients Controls OR (95 % CI) P
n = 159 (%) n = 298 (%)
mir-196a2 rs11614913 C/T C 148 (46.5) 278 (46.6) 1.00 (reference) 0.976
T 170 (52.4) 318 (53.4) 0.996 (0.758–1.308)
mir-499 rs3746444 A/G A 259 (81.4) 500 (83.9) 1.00 (reference) 0.348
G 59 (18.6) 96 (16.1) 1.186 (0.83–1.696)
mir-146a rs2910164 G/C C 193 (60.7) 378 (63.4) 1.00 (reference) 0.417
G 125 (39.3) 218 (36.6) 1.123 (0.849–1.486)
n number of individuals
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an overdominant model, and the heterozygous genotype
(CT genotype) was associated with decrease bladder
cancer risk.
The rs2910164 is a common G/C polymorphism which
resided at position +60 relative to the first nucleotide of
pre-miR-146a [21]. Compared with the G allele, the Gibbs
free was lower for rs2910164 C allele, suggesting that
the secondary structure was less stable for the C allele.
Genetic alterations might affect the expression and
function of mature miR-146a [11]. By now, the suscep-
tibility for carcinogenesis caused by the rs2910164 has
been demonstrated in a series of studies. Jazdzewski et
al. reported that the rs2910164 CC genotype is associ-
ated with lower risk in papillary thyroid carcinoma
[21]. Studies in hepatocellular carcinoma, cervical squa-
mous cell carcinoma, and bladder cancer also illustrate
analogous results [11, 22, 12]. In vitro, Wang et al.
found miR-146a can decrease bladder tumor cell
Table 3 Genotype frequencies of selected SNPs in pre-microRNAs among bladder cancer patients and controls and their association
with bladder cancer risk
Genetic model Genotype Patients Controls Logistic regressiona
n = 159 (%) n = 298 (%) OR (95 % CI) P
mir-196a2 rs11614913 C/T
Codominant T/T 52 (32.7 %) 76 (25.5 %) 1 0.015
C/T 66 (41.5 %) 166 (55.7 %) 0.58 (0.37–0.92)
C/C 41 (25.8 %) 56 (18.8 %) 1.08 (0.63–1.82)
Dominant T/T 52 (32.7 %) 76 (25.5 %) 1 0.1
C/T-C/C 107 (67.3 %) 222 (74.5 %) 0.70 (0.46–1.08)
Recessive T/T-C/T 118 (74.2 %) 242 (81.2 %) 1 0.085
C/C 41 (25.8 %) 56 (18.8 %) 1.49 (0.95–2.38)
Overdominant T/T-C/C 93 (58.5 %) 132 (44.3 %) 1 0.004
C/T 66 (41.5 %) 166 (55.7 %) 0.56 (0.38–0.83)
Log-additive — — — 1.00 (0.76–1.32) 0.98
mir-499 rs3746444 G/A
Codominant A/A 107 (67.3 %) 216 (72.5 %) 1 0.44
G/A 45 (28.3 %) 68 (22.8 %) 1.33 (0.86–2.08)
G/G 7 (4.4 %) 14 (4.7 %) 0.99 (0.39–2.53)
Dominant A/A 107 (67.3 %) 216 (72.5 %) 1 0.25
G/A-G/G 52 (32.7 %) 82 (27.5 %) 1.28 (0.84–1.96)
Recessive A/A-G/A 152 (95.6 %) 284 (95.3 %) 1 0.89
G/G 7 (4.4 %) 14 (4.7 %) 0.93 (0.37–2.38)
Overdominant A/A-G/G 114 (71.7 %) 230 (77.2 %) 1 0.2
G/A 45 (28.3 %) 68 (22.8 %) 1.33 (0.86–2.08)
Log-additive — — — 0.86 (0.61–1.20) 0.38
mir146a rs2910164 C/G
Codominant C/C 60 (37.7 %) 112 (37.6 %) 1 0.2
C/G 73 (45.9 %) 154 (51.7 %) 0.88 (0.58–1.35)
G/G 26 (16.4 %) 32 (10.7 %) 1.52 (0.83–2.78)
Dominant C/C 60 (37.7 %) 112 (37.6 %) 1 0.97
C/G-G/G 99 (62.3 %) 186 (62.4 %) 0.99(0.67–1.47)
Recessive C/C-C/G 133 (83.7 %) 266 (89.3 %) 1 0.091
G/G 26 (16.4 %) 32 (10.7 %) 1.61 (0.93–2.86)
Overdominant C/C-G/G 86 (54.1 %) 144 (48.3 %) 1 0.24
C/G 73 (45.9 %) 154 (51.7 %) 0.79 (0.54–1.16)
Log-additive — — — 0.88 (0.66–1.18) 0.4
aAdjusted by gender, age, smoking status, tumor stage, recurrence, and metastasis. Italicized values indicated a significant difference at the 5 % level
n number of individuals
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proliferation and that the expression level of miR-146a
is higher in rs2910164 C allele than G allele [11]. All of
these results demonstrated that the C allele may act in
a protective role and is more likely to exercise an inhibit-
ing effect on the tumorigenesis. But the studies conducted
in the breast/ovarian cancer showed an antithetical
conclusion [15]. This diversity might be a result of
organ-specific characteristics of rs2910164 and reflected
the detailed mechanism of SNPs on cancer is not fully
understood yet.
Invasive and metastatic nature was the main characteris-
tic of malignance tumor, which was the primary cause of
death for cancer patients [23]. Although exact molecular
mechanisms remain unclear, several studies indicate that
constitutive nuclear factor-κB (NF-κB) activity could
promote the invasion and migration of human cancers
[24, 25]. Known as the target of miR-146a, interleukin
1 receptor-associated kinase 1 (IRAK-1) plays an important
role in activation of NF-κB [26, 27]. It has been reported
that tumor cells would cease to be capable of invasion and
Table 4 Association between the selected SNPs in pre-microRNAs and tumor stage
Genetic model Genotype Invasive Superficial Logistic regressiona
n = 84 n = 75 OR (95 % CI) P
mir-196a2 rs11614913 C/T
Codominant T/T 27 (32.1 %) 25 (33.3 %) 1 0.68
C/T 33 (39.3 %) 33 (44 %) 0.63 (0.21–1.86)
C/C 24 (28.6 %) 17 (22.7 %) 1.45 (0.43–5.00)
Dominant T/T 27 (32.1 %) 25 (33.3 %) 1 0.39
C/T-C/C 57 (67.9 %) 50 (66.7 %) 0.65 (0.24–1.74)
Recessive T/T-C/T 60 (71.4 %) 58 (77.3 %) 1 0.83
C/C 24 (28.6 %) 17 (22.7 %) 1.12 (0.39–3.23)
Overdominant T/T-C/C 51 (60.7 %) 42 (56 %) 1 0.52
C/T 33 (39.3 %) 33 (44 %) 0.74 (0.28–1.91)
Log-additive — — — 0.82 (0.45–1.49) 0.51
mir-499 rs3746444 G/A
Codominant A/A 52 (61.9 %) 55 (73.3 %) 1 0.25
G/A 28 (33.3 %) 17 (22.7 %) 1.96 (0.67–5.88)
G/G 4 (4.8 %) 3 (4 %) 3.70 (0.50–25.00)
Dominant A/A 52 (61.9 %) 55 (73.3 %) 1 0.12
G/A-G/G 32 (38.1 %) 20 (26.7 %) 2.22 (0.81–5.88)
Recessive A/A-A/A 80 (95.2 %) 72 (96 %) 1 0.26
G/G 4 (4.8 %) 3 (4 %) 3.13 (0.44–25.00)
Overdominant A/A-G/G 56 (66.7 %) 58 (77.3 %) 1 0.27
G/A 28 (33.3 %) 17 (22.7 %) 1.82 (0.63–0.92)
Log-additive — — — 0.51 (0.23–1.13) 0.094
mir146a rs2910164 C/G
Codominant C/C 30 (35.7 %) 30 (40 %) 1 0.034
C/G 45 (53.6 %) 28 (37.3 %) 1.41 (0.50–4.00)
G/G 9 (10.7 %) 17 (22.7 %) 0.24 (0.06–1.01)
Dominant C/C 30 (35.7 %) 30 (40 %) 1 0.84
C/G-G/G 54 (64.3 %) 45 (60 %) 1.11 (0.42–2.89)
Recessive C/C-C/G 75 (89.3 %) 58 (77.3 %) 1 0.012
G/G 9 (10.7 %) 17 (22.7 %) 0.20 (0.05–0.72)
Overdominant C/C-G/G 39 (46.4 %) 47 (62.7 %) 1 0.097
C/G 45 (53.6 %) 28 (37.3 %) 2.17 (0.86–5.56)
Log-additive — — — 1.66 (0.84–3.31) 0.14
aAdjusted by gender, age, smoking status, tumor stage, recurrence, and metastasis. Italicized values indicated a significant difference at the 5 % level
n number of individuals
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migration if there was a downregulation of IRAK-1 induced
by miR-146a [26, 28, 29]. In addition, cell movement mode
was also believed to be a primary event in invasion and
metastasis [30]. WASP family verprolin homologous
protein 2 (WASF2) is involved in cell movement mode
and several studies have confirmed WASF2 could pro-
mote tumor progression [30–33]. Recently, Yao found
mir-146a can suppress the migration and invasion of
gastric cancer cells by reduction of WASF2 expression
[34]. Taken together, the above results suggest that
mir-146a can repress tumor invasions and metastases
in various ways.
In the present study, we found that SNP rs2910164 is
associated with the tumor stage in a recessive model,
with GG genotype frequency being significantly lower in
the group with invasive bladder cancer. Moreover, allele
G carriers (CG/GG genotype) are associated with metas-
tasis in a dominant model. As for bladder cancer, 70 %
patients belong to superficial cases [35]. Although the
comprehensive treatment such as transurethral resection
Table 5 Association between the selected SNPs in pre-microRNAs and metastasis
Genetic model Genotype Metastasis No metastasis Logistic regressiona
n = 132 n = 27 OR (95 % CI) P
mir-196a2 rs11614913 C/T
Codominant T/T 40 (30.3 %) 12 (44.4 %) 1 0.28
C/T 56 (42.4 %) 10 (37 %) 1.33 (0.47–3.85)
C/C 36 (27.3 %) 5 (18.5 %) 2.63 (0.77–9.09)
Dominant T/T 40 (30.3 %) 12 (44.4 %) 1 0.23
C/T-C/C 92 (69.7 %) 15 (55.6 %) 1.75 (0.70–4.35)
Recessive T/T-C/T 96 (72.7 %) 22 (81.5 %) 1 0.13
C/C 36 (27.3 %) 5 (18.5 %) 2.33 (0.74–7.14)
Overdominant T/T-C/C 76 (57.6 %) 17 (63 %) 1 0.87
C/T 56 (42.4 %) 10 (37 %) 1.08 (0.42–2.81)
Log-additive — — — 0.63 (0.35–1.14) 0.12
mir-499 rs3746444 G/A
Codominant A/A 89 (67.4 %) 18 (66.7 %) 1 0.37
G/A 38 (28.8 %) 7 (25.9 %) 1.72 (0.60–5.00)
G/G 5 (3.8 %) 2 (7.4 %) 0.46 (0.06–3.45)
Dominant A/A 89 (67.4 %) 18 (66.7 %) 1 0.45
G/A-G/G 43 (32.6 %) 9 (33.3 %) 0.69 (0.26–1.86)
Recessive A/A-G/A 127 (96.2 %) 25 (92.6 %) 1 0.35
G/G 5 (3.8 %) 2 (7.4 %) 0.37 (0.05–2.70)
Overdominant A/A-G/G 94 (71.2 %) 20 (74.1 %) 1 0.23
G/A 38 (28.8 %) 7 (25.9 %) 1.85 (0.65–5.26)
Log-additive — — — 0.89 (0.39–2.04) 0.78
mir146a rs2910164 C/G
Codominant C/C 46 (34.9 %) 14 (51.9 %) 1 0.081
C/G 62 (47 %) 11 (40.7 %) 2.27 (0.83–6.25)
G/G 24 (18.2 %) 2 (7.4 %) 5.00 (0.86–25.00)
Dominant C/G 46 (34.9 %) 14 (51.9 %) 1 0.04
C/G-G/G 86 (65.2 %) 13 (48.1 %) 2.63 (1.03–6.67)
Recessive C/G-C/G 108 (81.8 %) 25 (92.6 %) 1 0.12
G/G 24 (18.2 %) 2 (7.4 %) 3.33 (0.62–16.67)
Overdominant C/C-G/G 70 (53 %) 16 (59.3 %) 1 0.31
C/G 62 (47 %) 11 (40.7 %) 1.61 (0.63–4.17)
Log-additive — — — 0.45 (0.21–0.93) 0.025
aAdjusted by gender, age, smoking status, tumor stage, recurrence, and metastasis. Italicized values indicated a significant difference at the 5 % level
n number of individuals
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and postoperative intravesical chemotherapy are known
as the gold standard nowadays, the progression rate within
5 years is still high [36]. Our study demonstrates that
miR-146a rs2910164 is related to tumor stage and me-
tastasis of bladder cancer. These findings reveal more
clues about these SNPs of pre-miRNAs in the carcinogen-
esis of bladder cancer and may provide more information
about tumor progression that has not yet been observed
during an initial diagnosis.
Conclusions
In conclusion, we found that hsa-mir-196a2 rs11614913
C/T is associated with a significantly decreased risk of
bladder cancer in an overdominant model. In addition,
hsa-mir-146a rs2910164 GG genotype is associated with
clinical stage in a recessive model and CG/GG genotype
is associated with metastasis in a dominant model. It is
well known that the genetic polymorphism may execute
a different effect among different racial or ethnic popula-
tions [37]. Hence, future large-scale investigations in dif-
ferent population should be performed to validate our
results among other races and ethnicities.
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